Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.37 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 4/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18724747 | 1.00 | FFAR4 (0.39) | FFAR4LTB4RLTB4R2FASNMME | |
| SCHEMBL14900588 | 0.92 | RORC (0.39) | FFAR4LTB4RLTB4R2MME | |
| SCHEMBL18027484 | 0.90 | FFAR4 (0.39) | FFAR4LTB4RLTB4R2FASNMME | |
| SCHEMBL18691797 | 0.84 | GRM2 (0.42) | LTB4RLTB4R2 | |
| SCHEMBL14890375 | 0.84 | GRM2 (0.42) | LTB4RLTB4R2 | |
| SCHEMBL14919044 | 0.84 | GRM2 (0.42) | LTB4RLTB4R2 | |
| SCHEMBL16939237 | 0.83 | CHRM3 (0.36) | FFAR4FASNMMECHRM3ACE | |
| SCHEMBL19190870 | 0.82 | FFAR4 (0.39) | FFAR4HCRTR1HCRTR2 | |
| SCHEMBL22404869 | 0.81 | FASN (0.35) | FFAR4FASNMMECHRM3ACE | |
| SCHEMBL9929765 | 0.80 | CYP3A4 (0.36) | FASNMMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-09 | — | — | US | disclosed |
| EP-3256446-B1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID AS NEPRILYSIN INHIBITOR | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20210401808-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-12-30 | — | — | US | disclosed |
| US-11174219-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-11-16 | — | — | US | disclosed |
| US-11033533-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210155576-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10829438-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| EP-3259255-B1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20200281900-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-10 | — | — | US | disclosed |
| WO-2016130650-A1 | (2S, 4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID AS NEPRILYSIN INHIBITOR | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-18 | — | — | WO | disclosed |
| US-20160228395-A1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160228395-A1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160002148-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002148-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-01-07 | — | — | US | disclosed |
| US-9108934-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108934-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-08-18 | — | — | US | disclosed |
| WO-2015116786-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20150210690-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210690-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002148-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FFAR4 1442/4885LTB4R 1326/4885LTB4R2 1942/4885 |
| US-11174219-B2 | Neprilysin inhibitors | MME, REN, ACE | FFAR4 1442/4885LTB4R 1326/4885LTB4R2 1942/4885 |
| US-10829438-B2 | Neprilysin inhibitors | MME, REN, ACE | FFAR4 1442/4885LTB4R 1326/4885LTB4R2 1942/4885 |
| US-20210155576-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FFAR4 1442/4885LTB4R 1326/4885LTB4R2 1942/4885 |
| US-20200281900-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | MME, DNPEP, TMPRSS15 | FFAR4 140/4885LTB4R 1742/4885LTB4R2 2196/4885 |
| US-20210401808-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | MME, DNPEP, TMPRSS15 | FFAR4 140/4885LTB4R 1742/4885LTB4R2 2196/4885 |
| US-20160228395-A1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID | MME, DNPEP, CMA1 | FFAR4 297/4885LTB4R 706/4885LTB4R2 739/4885 |
| US-20150210690-A1 | NEPRILYSIN INHIBITORS | MME, REN, AGTR1 | FFAR4 2614/4885LTB4R 1171/4885LTB4R2 2001/4885 |
| US-11033533-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | MME, DNPEP, TMPRSS15 | FFAR4 141/4885LTB4R 1724/4885LTB4R2 2186/4885 |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | MME, DNPEP, TMPRSS15 | FFAR4 141/4885LTB4R 1724/4885LTB4R2 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.